Van ECK Associates Corp grew its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 9.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 123,100 shares of the biotechnology company’s stock after buying an additional 10,598 shares during the period. Van ECK Associates Corp owned 0.28% of United Therapeutics worth $14,426,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors also recently added to or reduced their stakes in UTHR. State Treasurer State of Michigan raised its position in shares of United Therapeutics by 1.6% during the second quarter. State Treasurer State of Michigan now owns 18,600 shares of the biotechnology company’s stock valued at $2,413,000 after buying an additional 300 shares during the last quarter. US Bancorp DE raised its position in shares of United Therapeutics by 3.2% during the second quarter. US Bancorp DE now owns 4,175 shares of the biotechnology company’s stock valued at $541,000 after buying an additional 128 shares during the last quarter. Bowling Portfolio Management LLC raised its position in shares of United Therapeutics by 16.6% during the second quarter. Bowling Portfolio Management LLC now owns 31,291 shares of the biotechnology company’s stock valued at $4,059,000 after buying an additional 4,460 shares during the last quarter. Eagle Global Advisors LLC purchased a new position in shares of United Therapeutics in the second quarter valued at $206,000. Finally, Great West Life Assurance Co. Can grew its holdings in shares of United Therapeutics by 8.9% in the second quarter. Great West Life Assurance Co. Can now owns 121,115 shares of the biotechnology company’s stock valued at $15,696,000 after purchasing an additional 9,948 shares in the last quarter.
UTHR has been the subject of a number of recent research reports. Oppenheimer Holdings, Inc. reissued a “buy” rating on shares of United Therapeutics in a report on Friday, September 8th. BidaskClub lowered shares of United Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, July 31st. ValuEngine raised shares of United Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, October 2nd. Zacks Investment Research raised shares of United Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, October 9th. Finally, HC Wainwright reissued a “hold” rating and issued a $95.00 target price on shares of United Therapeutics in a report on Thursday, October 26th. Five equities research analysts have rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $132.82.
In other United Therapeutics news, Director Christopher Causey sold 580 shares of United Therapeutics stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $134.48, for a total transaction of $77,998.40. Following the completion of the transaction, the director now directly owns 3,295 shares of the company’s stock, valued at $443,111.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Martine A. Rothblatt sold 1,274 shares of United Therapeutics stock in a transaction on Thursday, September 21st. The stock was sold at an average price of $116.07, for a total transaction of $147,873.18. Following the transaction, the chief executive officer now directly owns 2,343 shares of the company’s stock, valued at $271,952.01. The disclosure for this sale can be found here. Insiders have sold 22,641 shares of company stock valued at $2,765,186 over the last ninety days. 7.80% of the stock is owned by insiders.
United Therapeutics Corporation (UTHR) opened at $125.01 on Monday. The company has a market cap of $5,401.81, a price-to-earnings ratio of 11.02 and a beta of 1.38. United Therapeutics Corporation has a one year low of $112.01 and a one year high of $169.89.
United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported $6.27 EPS for the quarter, topping the consensus estimate of $4.01 by $2.26. The company had revenue of $445.50 million during the quarter, compared to analyst estimates of $426.43 million. United Therapeutics had a net margin of 30.50% and a return on equity of 26.24%. United Therapeutics’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $4.23 earnings per share. analysts predict that United Therapeutics Corporation will post 12.29 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This piece was originally published by Transcript Daily and is the property of of Transcript Daily. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://transcriptdaily.com/2017/11/27/united-therapeutics-corporation-uthr-holdings-raised-by-van-eck-associates-corp.html.
United Therapeutics Profile
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR).
Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.